ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

Vaxelis suspension for injection in pre-filled syringe
Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus type b conjugate vaccine (adsorbed).

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One dose (0.5 mL) contains:

Diphtheria Toxoid\(^1\) not less than 20 IU\(^6\)
Tetanus Toxoid\(^1\) not less than 40 IU\(^6\)
**Bordetella pertussis** antigens\(^1\)
  - Pertussis Toxoid (PT) 20 micrograms
  - Filamentous Haemagglutinin (FHA) 20 micrograms
  - Pertactin (PRN) 3 micrograms
  - Fimbriae Types 2 and 3 (FIM) 5 micrograms
Hepatitis B surface antigen\(^2,3\) 10 micrograms
Poliovirus (Inactivated)\(^4\)
  - Type 1 (Mahoney) 40 D antigen units\(^5\)
  - Type 2 (MEF-1) 8 D antigen units\(^5\)
  - Type 3 (Saukett) 32 D antigen units\(^5\)
*Haemophilus influenzae* type b polysaccharide
  - (Polyribosylribitol Phosphate) 3 micrograms
  - Conjugated to meningococcal protein\(^2\) 50 micrograms

\(^1\) adsorbed on aluminium phosphate (0.17 mg Al\(^{3+}\))
\(^2\) adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.15 mg Al\(^{3+}\))
\(^3\) produced in yeast (*Saccharomyces cerevisiae*) cells by recombinant DNA technology
\(^4\) produced in Vero cells
\(^5\) or equivalent antigenic quantity determined by a suitable immunochemical method
\(^6\) or equivalent activity determined by an immunogenicity evaluation.

The vaccine may contain traces of glutaraldehyde, formaldehyde, neomycin, streptomycin, polymyxin B, and bovine serum albumin which are used during the manufacturing process (see section 4.3).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Suspension for injection (injection).
Uniform, cloudy, white to off-white suspension.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Vaxelis (DTaP-HB-IPV-Hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by *Haemophilus influenzae* type b (Hib).

The use of Vaxelis should be in accordance with official recommendations.
4.2 Posology and method of administration

Posology

Primary vaccination:

The primary vaccination schedule consists of two or three doses, with an interval of at least 1 month between doses, and may be given from 6 weeks of age, in accordance with the official recommendations.

Where a dose of hepatitis B vaccine is given at birth, Vaxelis can be used for supplementary doses of hepatitis B vaccine from the age of 6 weeks. If a second dose of hepatitis B vaccine is required before this age, monovalent hepatitis B vaccine should be used. Vaxelis can be used for a mixed hexavalent/pentavalent/hexavalent combined vaccine immunisation schedule.

Booster vaccination:

After a 2-dose or a 3-dose primary series vaccination with Vaxelis, a booster dose should be given at least 6 months after the last priming dose. Vaxelis may be used as a booster dose in children who received another hexavalent vaccine for their primary series. When a booster dose with a hexavalent DTaP (diphtheria, tetanus, and acellular pertussis) containing vaccine is not available, a dose of Hib vaccine must be administered, as a minimum.

Other paediatric population

The safety and efficacy of Vaxelis in infants less than 6 weeks of age have not been established. No data are available.

No data are available in older children (see sections 4.8 and 5.1).

Method of administration

Vaxelis should only be administered by intramuscular (IM) injection. The recommended injection sites are the anterolateral area of the thigh (preferred site for infants under one year of age) or the deltoid muscle of the upper arm.

For instructions on handling of the medicinal product before administration, see section 6.6.

4.3 Contraindications

History of an anaphylactic reaction after a previous administration of Vaxelis or a vaccine containing the same components or constituents.

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or to trace residuals (glutaraldehyde, formaldehyde, neomycin, streptomycin, polymyxin B, and bovine serum albumin).

Encephalopathy of unknown aetiology, occurring within 7 days following prior vaccination with a pertussis containing vaccine. In these circumstances, pertussis vaccination should be discontinued, and the vaccination course should be continued with diphtheria, tetanus, hepatitis B, poliomyelitis, and Hib vaccines.

Uncontrolled neurologic disorder or uncontrolled epilepsy: pertussis vaccination should not be administered until treatment for the condition has been established, the condition has stabilised, and the benefit clearly outweighs the risk.
4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Protection

Vaxelis will not prevent disease caused by pathogens other than Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, hepatitis B virus, poliovirus or Haemophilus influenzae type b. However, it can be expected that hepatitis D will be prevented by immunisation as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.

Vaxelis will not protect against hepatitis infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E or by other liver pathogens.

Because of the long incubation period of hepatitis B, it is possible for unrecognised hepatitis B infection to be present at the time of vaccination. The vaccine may not prevent hepatitis B infection in such cases.

Vaxelis does not protect against disease caused by Haemophilus influenzae other than type b or by other microorganisms that cause invasive disease such as meningitis or sepsis, including N. meningitidis.

As with any vaccine, a protective immune response may not be elicited in all vaccinees.

Prior to immunisation

Vaccination should be preceded by a review of the individual's medical history (in particular, previous vaccinations and possible adverse reactions).

As with all injectable vaccines, appropriate medical treatment and supervision should be readily available for immediate use in case of a rare anaphylactic reaction following the administration of the vaccine (see section 4.3).

As with other vaccines, administration of Vaxelis should be postponed in children suffering from moderate to severe acute disease, with or without fever. The presence of a minor illness and /or low-grade fever does not constitute a contraindication.

If any of the following events have occurred after administration of a pertussis-containing vaccine, the decision to administer further doses of a pertussis-containing vaccine should be carefully considered:

- Temperature of ≥40.5°C within 48 hours, not attributable to another identifiable cause
- Collapse or shock-like state (hypotonic-hyporesponsive episode [HHE]) within 48 hours of vaccination
- Persistent crying lasting ≥3 hours, occurring within 48 hours of vaccination
- Convulsions with or without fever, occurring within 3 days of vaccination.

There may be some circumstances, such as high incidence of pertussis, when the potential benefits outweigh possible risks.

If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior vaccine containing tetanus toxoid, the decision to give any vaccine containing tetanus toxoid, including Vaxelis, should be based on careful consideration of the potential benefits and possible risks.

A history of febrile convulsions, a family history of convulsions, or Sudden Infant Death Syndrome
(SIDS) do not constitute a contraindication for the use of Vaxelis. Individuals with a history of febrile convulsions should be closely followed up as febrile convulsions may occur within 2 to 3 days post vaccination.

Do not administer by intravascular, intradermal or subcutaneous injection.

**Special populations**

**Premature infants**
Limited data from 111 pre-term newborn infants in clinical trials indicate that Vaxelis can be given to premature infants. The immune responses to Vaxelis in these infants were generally similar to those of the overall study population. However, a lower immune response may be observed, and the level of clinical protection is unknown.

The potential risk of apnoea and the need for respiratory monitoring for 48-72 hours should be considered when administering the primary immunisation series to very premature infants (born ≤28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.

**Genetic Polymorphism**
Immune responses to the vaccine have not been studied in the context of genetic polymorphism.

**Immunocompromised children**
The immunogenicity of the vaccine may be reduced by immunosuppressive treatment or immunodeficiency. It is recommended to postpone vaccination until the end of such treatment or disease. Nevertheless, vaccination of individuals with chronic immunodeficiency such as HIV infection is recommended even if the antibody response may be limited.

**Blood disorders**
As with all injectable vaccines, the vaccine must be administered with caution to individuals with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration.

**Interference with laboratory testing**
Since the Hib capsular polysaccharide antigen is excreted in the urine, a false positive urine test can be observed using sensitive tests, for at least 30 days following vaccination. Other tests should be performed in order to confirm Hib infection during this period.

**Sodium**
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.

### 4.5 Interaction with other medicinal products and other forms of interaction

Vaxelis may be administered simultaneously with pneumococcal polysaccharide conjugate vaccines, rotavirus vaccines, measles, mumps, rubella (MMR) and varicella containing vaccines, meningococcal B and C conjugate vaccines.

Data from a clinical study indicate that, when Vaxelis is co-administered with pneumococcal conjugate vaccine (PCV13), the rate of fever is higher following the booster dose in the second year of life compared to the primary series. Almost all fevers were mild or moderate (<39.5°C) and transient (duration of ≤2 days) (see section 4.8).

Co-administration of Vaxelis with other injectable vaccines must be carried out at separate injection
sites and, preferably, separate limbs.

Vaxelis should not be mixed with any other vaccine or other parenterally administered medicinal products.

Immunosuppressive therapy may interfere with the development of expected immune response (see section 4.4).

Due to an increased risk of fever, tenderness at the injection site, change in eating habits and irritability when a different hexavalent vaccine with a similar reactogenicity profile to Vaxelis was co-administered with Meningococcal B vaccine, separate vaccinations can be considered.

4.6 Fertility, pregnancy and lactation

This vaccine is not intended for administration to women of child-bearing potential.

4.7 Effects on ability to drive and use machines

Vaxelis is indicated for infants and toddlers; therefore, no studies have been conducted to assess its effect on the ability to drive or use machines. It is expected that the vaccine will have negligible or no effects in this regard.

4.8 Undesirable effects

Summary of the safety profile

The most frequently reported adverse reactions after Vaxelis administration were irritability, crying, somnolence, injection site reactions (pain, erythema, swelling), pyrexia (≥38°C), decreased appetite, and vomiting.

The safety of Vaxelis in children over 15 months of age has not been studied in clinical trials.

In a clinical study where Vaxelis was administered concomitantly with Prevenar 13 (PCV13) as a booster dose of both vaccines, fever ≥38.0°C was reported in 52.5% of children, compared to 33.1% to 40.7% of children during the primary series. Fever ≥39.5°C was observed in 3.7% of children (post-booster) and 0.2% to 0.8% of children (post-primary) receiving Vaxelis with PCV13 (see sections 4.4 and 4.5). Almost all fevers after primary and booster doses were mild or moderate (<39.5°C) and transient (duration of ≤2 days).

Tabulated list of adverse reactions

The following convention has been used for the classification of adverse reactions:

| Very common (≥1/10) |
| Common (≥1/100 to <1/10) |
| Uncommon (≥1/1,000 to <1/100) |
| Rare (≥1/10,000 to <1/1,000) |
| Very rare (<1/10,000) |
| Not known (cannot be estimated from the available data) |

Table 1: List of Adverse Reactions from clinical trials and post marketing surveillance

<table>
<thead>
<tr>
<th>MedDRA System Organ Class</th>
<th>Frequency</th>
<th>Adverse Reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Uncommon</td>
<td>Rhinitis</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Uncommon</td>
<td>Lymphadenopathy</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Rare</td>
<td>Hypersensitivity*, Anaphylactic reaction*</td>
</tr>
<tr>
<td>MedDRA System Organ Class</td>
<td>Frequency</td>
<td>Adverse Reactions</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>-----------</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Very Common</td>
<td>Decreased appetite</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Increased appetite</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Uncommon</td>
<td>Sleep disorders including insomnia, restlessness</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Very Common</td>
<td>Somnolence</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Hypotonia</td>
</tr>
<tr>
<td></td>
<td>Not known</td>
<td>Convulsions with or without fever(^{\dagger}), hypotonic-hyporesponsive episode (HHE)(^{\dagger})</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Uncommon</td>
<td>Pallor</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Uncommon</td>
<td>Cough</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Very Common</td>
<td>Vomiting</td>
</tr>
<tr>
<td></td>
<td>Common</td>
<td>Diarrhoea</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Abdominal pain</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Uncommon</td>
<td>Rash, hyperhidrosis</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Very Common</td>
<td>Crying, irritability, injection site erythema, injection site pain, injection site swelling Pyrexia</td>
</tr>
<tr>
<td></td>
<td>Common</td>
<td>Injection site bruising, injection site induration, injection site nodule</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Injection site rash, injection site warmth, fatigue</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Extensive swelling of vaccinated limb(^{\dagger})</td>
</tr>
</tbody>
</table>

\(^{\dagger}\) Based on post-marketing reports.

\(^{\dagger}\) Based on post-marketing reports. Because these events were reported from a population of uncertain size, it is generally not possible to reliably estimate their frequency or to establish a causal relationship to the vaccine. See section 4.4.

\(^{\dagger}\) Estimated frequency based on post-marketing reports and not reported in clinical trials with >5,200 participants.

**Premature infants**

Apnoea in very premature infants (≤28 weeks of gestation) (see section 4.4).

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 **Overdose**

No cases of overdose have been reported.

5. **PHARMACOLOGICAL PROPERTIES**

5.1 **Pharmacodynamic properties**

Pharmacotherapeutic group: Vaccines, Bacterial and viral vaccines combined, ATC code: J07CA09
Immunogenicity after primary series and booster doses

The primary vaccination schedules used in clinical studies were: 2, 4 months of age without hepatitis B vaccination at birth; 2, 3, 4 months of age without hepatitis B vaccination at birth; and 2, 4, 6 months of age with and without hepatitis B vaccination at birth. The booster dose in clinical studies was given at 11-12 months of age after a 2-dose primary series, at 12 months of age after a 3-dose primary series (2, 3, 4 months), and at 15 months of age after a 3-dose primary series (2, 4, 6 months). Results obtained for each component of the vaccine are summarised in Table 2 and Table 3.

Table 2: Seroprotection/Vaccine Response Rates One Month After the Primary Vaccination Series

<table>
<thead>
<tr>
<th>Antibody Thresholds</th>
<th>Two doses</th>
<th>Three doses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2, 4 months</td>
<td>2, 3, 4 months</td>
</tr>
<tr>
<td></td>
<td>N = 319-609</td>
<td>N = 498-550</td>
</tr>
<tr>
<td>Anti-diphtheria (≥ 0.01 IU/mL)</td>
<td>98.3</td>
<td>99.8</td>
</tr>
<tr>
<td>Anti-tetanus (≥ 0.01 IU/mL)</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-PT (vaccine response)¹</td>
<td>98.1</td>
<td>99.4</td>
</tr>
<tr>
<td>Anti-FHA (vaccine response)²</td>
<td>89.0</td>
<td>89.0</td>
</tr>
<tr>
<td>Anti-PRN (vaccine response)³</td>
<td>80.3</td>
<td>86.7</td>
</tr>
<tr>
<td>Anti-FIM (vaccine response)⁴</td>
<td>93.3</td>
<td>97.2</td>
</tr>
<tr>
<td>Anti-Polio type 1 (≥ 1:8 dilution)</td>
<td>93.8</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-Polio type 2 (≥ 1:8 dilution)</td>
<td>98.0</td>
<td>99.8</td>
</tr>
<tr>
<td>Anti-Polio type 3 (≥ 1:8 dilution)</td>
<td>92.9</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-HBs Ag (≥ 10 mIU/mL)</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>With hepatitis B vaccination at birth</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Without hepatitis B vaccination at birth</td>
<td>98.1</td>
<td>97.8</td>
</tr>
<tr>
<td>Anti-PRP (≥ 0.15 µg/mL)</td>
<td>96.6</td>
<td>98.4</td>
</tr>
</tbody>
</table>

¹Vaccine response: If pre-dose 1 antibody concentration < lower limit of quantification (LLOQ), then the post-vaccination series antibody concentration was ≥ LLOQ; if pre-dose 1 antibody concentration ≥ LLOQ, then the post-vaccination series antibody concentration was ≥ pre-dose 1 levels. LLOQ = 4 EU/mL are for anti-PT, anti-PRN and anti-FIM; and LLOQ = 3 EU/mL for anti-FHA

²N=89 subjects from a separate study
Table 3: Seroprotection/Vaccine Response Rates One Month After Booster Vaccination

<table>
<thead>
<tr>
<th>Antibody Thresholds</th>
<th>Booster at 11-12 months, after primary doses at 2, 4, months</th>
<th>Booster at 12 months after primary doses at 2, 3, 4 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>N = 377-591</td>
<td>N = 439-551</td>
<td></td>
</tr>
<tr>
<td>N = 377-591</td>
<td>N = 439-551</td>
<td></td>
</tr>
<tr>
<td>Anti-diphtheria (≥ 0.1 IU/mL)</td>
<td>98.6</td>
<td>99.8</td>
</tr>
<tr>
<td>Anti-tetanus (≥ 0.1 IU/mL)</td>
<td>99.8</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-PT (vaccine response)</td>
<td>99.1</td>
<td>99.8</td>
</tr>
<tr>
<td>Anti-FHA (vaccine response)</td>
<td>97.4</td>
<td>97.2</td>
</tr>
<tr>
<td>Anti-PRN (vaccine response)</td>
<td>96.9</td>
<td>99.3</td>
</tr>
<tr>
<td>Anti-FIM (vaccine response)</td>
<td>98.3</td>
<td>99.6</td>
</tr>
<tr>
<td>Anti-Polio type 1 (≥ 1:8 dilution)</td>
<td>99.3</td>
<td>99.8</td>
</tr>
<tr>
<td>Anti-Polio type 2 (≥ 1:8 dilution)</td>
<td>99.8</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-Polio type 3 (≥ 1:8 dilution)</td>
<td>99.5</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-HBs Ag (≥ 10 mIU/mL)</td>
<td>98.1</td>
<td>99.6</td>
</tr>
<tr>
<td>Anti-PRP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 0.15 µg/mL</td>
<td>99.6</td>
<td>99.5</td>
</tr>
<tr>
<td>≥ 1.0 µg/mL</td>
<td>89.9</td>
<td>95.0</td>
</tr>
</tbody>
</table>

aVaccine response: If pre-dose 1 antibody concentration < LLOQ, then post-booster antibody concentration should be ≥ LLOQ; If pre-dose 1 antibody concentration ≥ LLOQ, then the post-booster antibody concentration should be ≥ pre-dose 1 levels. LLOQ = 4 EU/mL are for anti-PT, anti-PRN and anti-FIM; and LLOQ = 3 EU/mL for anti-FHA.

bDid not receive hepatitis B vaccine at birth.

Regarding PT and FIM, similar response rates and higher GMCs were observed both post-primary and post-booster in comparison to control vaccine. Lower FHA, PRN, IPV1 (Inactivated poliovirus vaccine) and IPV3 immune responses were observed after a 2-dose primary schedule (2, 4 months), although the clinical relevance of these data remains uncertain. Pertussis response rates were similar to the control vaccine for all pertussis antigens after the booster dose.

The immunogenicity of Vaxelis administered to children over 15 months of age has not been studied in clinical trials.

In an open-label study, Vaxelis was given as a booster dose to 167 healthy children approximately 11-13 months of age who previously received a 2-dose primary series of either Vaxelis (N=85) or another hexavalent vaccine with 2 pertussis components (DTaP-HB-IPV-Hib; N=82) as part of routine vaccination. A booster dose of Vaxelis was well tolerated and induced an increase of the humoral immune responses to all antigens. At 30 days post-boost, at least 89% of the children had a seroresponse defined as protective against diphtheria, tetanus, hepatitis B, poliomyelitis, and invasive Haemophilus influenzae type b disease.

Persistence of the immune response

**Hepatitis B immune memory**

The persistence of immune responses was evaluated in children up to 8 years after primary vaccination with Vaxelis. The proportions of these children with anti-HBsAg ≥ 10 mIU/mL after having received Vaxelis either at 2, 4, and 11-12 months or at 2, 3, 4, and 12 months of age, respectively, were:

- 65.8% (119 of 181) and 70.2% (134 of 191), respectively, at 4 or 5 years of age;
- 40.9% (38 of 93) and 49.1% (55 of 112), respectively, at 8 or 9 years of age.

A hepatitis B vaccine challenge dose was given to children 8 or 9 years of age. Approximately 1 month after this challenge dose, the proportions with anti-HBsAg ≥ 10 mIU/mL were 100% (93 of 93) and 99.1% (108 of 109), respectively. These data demonstrate an anamnestic response after a challenge dose, indicating the persistence of hepatitis B immune memory in persons who previously received Vaxelis.
Persistence of antibodies to pertussis antigens

The persistence of pertussis antibodies was measured in children 4 or 5 years of age who had received Vaxelis at 2, 4, and 11-12 months of age. The percentages of these children with anti-pertussis antibodies ≥ the lower limit of quantification were: anti-PT 58.4%, anti-FHA 80.9%, anti-PRN 66.1%, and anti-FIM 94.4%.

5.2 Pharmacokinetic properties

No pharmacokinetic studies have been performed.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium phosphate
Water for injections

For adjuvants, see section 2.

6.2 Incompatibilities

In the absence of compatibility studies, this vaccine must not be mixed with other vaccines or medicinal products.

6.3 Shelf life

4 years.

6.4 Special precautions for storage

Store in a refrigerator (2°C – 8°C).
Do not freeze.
Keep the pre-filled syringe in the outer carton in order to protect from light.

Stability data indicate that the vaccine is stable at temperatures up to 25°C for 228 hours. At the end of this period Vaxelis should be used or discarded. These data are intended to guide healthcare professionals in case of a temporary temperature excursion only.

6.5 Nature and contents of container

0.5 mL suspension in pre-filled syringe (type I glass) with plunger stopper (butyl) and tip cap (butyl), without needle – pack size of 1 or 10.
0.5 mL suspension in pre-filled syringe (type I glass) with plunger stopper (butyl) and tip cap (butyl), without needle – multipack of 5 packs of 10.
0.5 mL suspension in pre-filled syringe (type I glass) with plunger stopper (butyl) and tip cap (butyl), with 1 separate needle – pack size of 1 or 10.
0.5 mL suspension in pre-filled syringe (type I glass) with plunger stopper (butyl) and tip cap (butyl), with 2 separate needles – pack size of 1 or 10.

Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling

Instructions for use

Prior to administration, the pre-filled syringe should be shaken gently in order to obtain a homogeneous, whitish, cloudy suspension.

The suspension should be visually inspected, prior to administration, for foreign particulate matter and/or variation of physical appearance. If either is observed, discard the pre-filled syringe.

The needle must be fitted firmly on to the pre-filled syringe, rotating it by a one-quarter turn.

Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

MCM Vaccine B.V.
Robert Boyleweg 4
2333 CG Leiden
The Netherlands

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1079/001
EU/1/15/1079/002
EU/1/15/1079/003
EU/1/15/1079/004
EU/1/15/1079/005
EU/1/15/1079/006
EU/1/15/1079/007

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 15 February 2016
Date of latest renewal: 24 September 2020

10. DATE OF REVISION OF THE TEXT

{MM/YYYY}

Detailed information on this medicinal product is available on the website of the European Medicines Agency https://www.ema.europa.eu.
ANNEX II

A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers of the biological active substances

Merck Sharp & Dohme LLC  
770 Sumneytown Pike  
West Point, PA 19486  
USA

Sanofi Pasteur SA  
1541 Avenue Marcel Mérieux  
69280 Marcy l'Etoile  
France

Sanofi Pasteur Limited  
1755 Steeles Avenue West Toronto  
Ontario M2R 3T4  
Canada

Name and address of the manufacturer responsible for batch release

MCM Vaccine B.V.  
Robert Boyleweg 4  
2333 CG Leiden.  
The Netherlands

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

- **Official batch release**

In accordance with Article 114 of Directive 2001/83/EC, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- **Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- **Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.
An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Carton for prefilled syringe without needle, with one separate needle, with two separate needles. Pack of 1 or 10.

1. NAME OF THE MEDICINAL PRODUCT

Vaxelis suspension for injection in pre-filled syringe
Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus type b conjugate vaccine (adsorbed).

DTaP-HB-IPV-Hib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

1 dose (0.5 mL):
- Diphtheria Toxoid ≥ 20 IU
- Tetanus Toxoid ≥ 40 IU
- Bordetella pertussis antigens (Pertussis Toxoid/Filamentous Haemagglutinin/ Fimbriae types 2 and 3/Pertactin) 20/20/5/3 μg
- Hepatitis B surface antigen 10 μg
- Poliovirus (Inactivated) Types 1/2/3 40/8/32 DU

Haemophilus influenzae type b polysaccharide conjugated to meningococcal protein 3 mg
- 1 adsorbed on AlPO₄ 0.17 mg Al³⁺
- 2 adsorbed on AlHO₃PS³⁻ 0.15 mg Al³⁺

3. LIST OF EXCIPIENTS

Excipients:
- Sodium phosphate
- Water for injections

4. PHARMACEUTICAL FORM AND CONTENTS

Suspension for injection
1 pre-filled syringe (0.5 mL) without needle
10 pre-filled syringes (0.5 mL) without needle
1 pre-filled syringe (0.5 mL) with 1 needle
1 pre-filled syringe (0.5 mL) with 2 needles
10 pre-filled syringes (0.5 mL) with 10 needles
10 pre-filled syringes (0.5 mL) with 20 needles

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Intramuscular use.
Shake before use.
Read the package leaflet before use.
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze.
Keep the vaccine in the outer carton in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

MCM Vaccine B.V.
Robert Boyleweg 4
2333 CG Leiden
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1079/001
EU/1/15/1079/002
EU/1/15/1079/003
EU/1/15/1079/004
EU/1/15/1079/005
EU/1/15/1079/006

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE
16. INFORMATION IN BRAILLE

Justification for not including Braille accepted

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC
SN
NN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING


1. NAME OF THE MEDICINAL PRODUCT

Vaxelis suspension for injection in pre-filled syringe
Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus type b conjugate vaccine (adsorbed).

DTaP-HB-IPV-Hib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

1 dose (0.5 mL)
Diphtheria Toxoid¹ ≥ 20 IU
Tetanus Toxoid¹ ≥ 40 IU
Bordetella pertussis antigens¹
(Pertussis Toxoid/Filamentous Haemagglutinin/ Fimbriae types 2 and 3/Pertactin) 20/20/5/3 µg
Hepatitis B surface antigen² 10 µg
Poliovirus (Inactivated) Types 1/2/3 40/8/32 DU
Haemophilus influenzae type b polysaccharide 3 µg
congjugated to meningococcal protein² 50 µg

¹adsorbed on AlPO₄ 0.17 mg Al³⁺
²adsorbed on AlHO₄PS⁻³ 0.15 mg Al³⁺

3. LIST OF EXCIPIENTS

Excipients:
Sodium phosphate
Water for injections

4. PHARMACEUTICAL FORM AND CONTENTS

Suspension for injection
10 pre-filled syringes (0.5 mL) without needle

Component of a multipack, cannot be sold separately

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Intramuscular use.
Shake before use.
Read the package leaflet before use.
6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**

   Store in a refrigerator. Do not freeze.  
   Keep the vaccine in the outer carton in order to protect from light.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

   MCM Vaccine B.V.  
   Robert Boyleweg 4  
   2333 CG Leiden  
   The Netherlands

12. **MARKETING AUTHORISATION NUMBER(S)**

   EU/1/15/1079/007

13. **BATCH NUMBER**

   Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**
16. INFORMATION IN BRAILLE
Justification for not including Braille accepted

17. UNIQUE IDENTIFIER – 2D BARCODE
Not applicable.

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA
Not applicable.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Carton for multipack containing 5 packs of 10 prefilled syringes without needle. Multipack of 50 (with blue box).

1. NAME OF THE MEDICINAL PRODUCT

Vaxelis suspension for injection in pre-filled syringe
Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus type b conjugate vaccine (adsorbed).

DTaP-HB-IPV-Hib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

1 dose (0.5 mL)

Diphtheria Toxoid\(^1\) ≥ 20 IU
Tetanus Toxoid\(^1\) ≥ 40 IU

*Bordetella pertussis* antigens\(^1\)
(Pertussis Toxoid/Filamentous Haemagglutinin/ Fimbriae types 2 and 3/Pertactin) 20/20/5/3 µg

Hepatitis B surface antigen\(^2\) 10 µg

Poliovirus (Inactivated) Types 1/2/3 40/8/32 DU

*Haemophilus influenzae* type b polysaccharide 3 µg

conjugated to meningococcal protein\(^2\) 50 µg

\(^1\)adsorbed on AlPO\(_4\) 0.17 mg Al\(^{3+}\)

\(^2\)adsorbed on AlHO\(_9\)PS\(^{-3}\) 0.15 mg Al\(^{3+}\)

3. LIST OF EXCIPIENTS

Excipients:
Sodium phosphate
Water for injections

4. PHARMACEUTICAL FORM AND CONTENTS

Suspension for injection
Multipack: 50 (5 packs of 10) pre-filled syringes (0.5 mL) without needle

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Intramuscular use.
Shake before use.
Read the package leaflet before use.
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Keep the vaccine in the outer carton in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

MCM Vaccine B.V.
Robert Boyleweg 4
2333 CG Leiden
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/15/1079/007

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted
17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC
SN
NN
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Label – Prefilled Syringe</strong></td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

   - Vaxelis injection
   - IM
   - DTaP-HB-IPV-Hib

2. **METHOD OF ADMINISTRATION**

3. **EXPIRY DATE**

   - EXP

4. ** BATCH NUMBER**

   - Lot

5. **CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

   - 1 dose

6. **OTHER**

   - MCM Vaccine B.V.
B. PACKAGE LEAFLET
Package leaflet: Information for the user

Vaxelis suspension for injection in pre-filled syringe
Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus type b conjugate vaccine (adsorbed).

Read all of this leaflet carefully before your child is vaccinated with this medicine because it contains important information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor, pharmacist or nurse.
• This medicine has been prescribed for your child only. Do not pass it on to others.
• If your child get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Vaxelis is and what it is used for
2. What you need to know before Vaxelis is given to your child
3. How to use Vaxelis
4. Possible side effects
5. How to store Vaxelis
6. Contents of the pack and other information

1. What is Vaxelis and what it is used for

Vaxelis is a vaccine, which helps to protect your child against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and serious diseases caused by *Haemophilus influenzae* type b. Vaxelis is given to children from the age of six weeks.

The vaccine works by causing the body to produce its own protection (antibodies) against the bacteria and viruses that cause the following diseases:
• Diphtheria: a bacterial infection that usually first affects the throat, causing pain and swelling which can lead to suffocation. The bacteria also make a toxin (poison) that can damage the heart, kidneys and nerves.
• Tetanus (often called lock jaw): caused by the tetanus bacteria entering a deep wound. The bacteria make a toxin (poison) that causes spasms of the muscles, leading to inability to breathe and the possibility of suffocation.
• Pertussis (often called whooping cough): a highly infectious illness that affects the airways. It causes severe coughing that may lead to problems with breathing. The coughing often has a “whooping” sound. The cough may last for one to two months or longer. Whooping cough can also cause ear infections, chest infections (bronchitis) which may last a long time, lung infections (pneumonia), fits, brain damage and even death.
• Hepatitis B: caused by the hepatitis B virus. It causes the liver to become swollen (inflamed). In some people, the virus can stay in the body for a long time, and can eventually lead to serious liver problems, including liver cancer.
• Poliomyelitis (often just called polio): caused by viruses that affect the nerves. It can lead to paralysis or muscle weakness most commonly of the legs. Paralysis of the muscles that control breathing and swallowing can be fatal.
• *Haemophilus influenzae* type b infections (often just called Hib infections): serious bacterial infections causing meningitis (inflammation of the outer covering of the brain), which can lead to brain damage, deafness, epilepsy, or partial blindness. Infection can also cause inflammation and swelling of the throat, leading to difficulties in swallowing and breathing, and infection can affect other parts of the body such as the blood, lungs, skin, bones, and joints.

Important information about the protection provided
• Vaxelis will only help to prevent these diseases caused by the bacteria and viruses targeted by
the vaccine. Vaxelis does not protect your child against diseases caused by other bacteria and viruses that may cause similar symptoms.

- The vaccine does not contain any live bacteria or viruses and it cannot cause any of the infectious diseases against which it protects.
- As with any vaccine, Vaxelis may not protect 100% of children who receive the vaccine.

2. What you need to know before Vaxelis is given to your child

To make sure that Vaxelis is suitable for your child, it is important to talk to your doctor or nurse if any of the points below apply to your child. If there is anything you do not understand, ask your doctor, pharmacist or nurse to explain.

Do not use Vaxelis if your child:

- has had shortness of breath or swelling of the face (anaphylactic reaction) after administration of a previous dose of Vaxelis.
- is allergic (hypersensitive)
  - to Vaxelis vaccine or any diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B or Hib containing vaccines,
  - to any ingredients listed in section 6,
  - to glutaraldehyde, formaldehyde, neomycin, streptomycin, polymyxin B (antibiotics) and bovine serum albumin, as these substances are used during the manufacturing process.
- has suffered from a severe reaction affecting the brain (encephalopathy) within 7 days of a prior dose of a pertussis vaccine (acellular or whole cell pertussis).
- has an uncontrolled condition or severe illness affecting the brain and nervous system (uncontrolled neurologic disorder) or uncontrolled epilepsy.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before vaccination if your child:

- has a moderate to severe acute disease, with or without fever (e.g. sore throat, cough, cold or flu). Vaccination with Vaxelis may need to be delayed until your child is better.
- has any of the following events after receiving a vaccine against pertussis (whooping cough), as the decision to give further doses of pertussis containing vaccine will need to be carefully considered:
  - had a fever of 40.5°C or above within 48 hours not due to another identifiable cause.
  - became floppy, unresponsive or unconscious after the previous vaccination, within 48 hours of vaccination.
  - cried continuously and could not be comforted for more than 3 hours within 48 hours of vaccination.
  - had a fit (convulsions) with or without fever, within 3 days of vaccination.
- previously had Guillain-Barré syndrome (temporary loss of feeling and movement) after being given a vaccine containing tetanus toxoid (an inactivated form of tetanus toxin). Your doctor will decide whether to give Vaxelis to your child.
- is receiving a treatment (such as steroids, chemotherapy or radiotherapy) or has a disease that suppresses or weakens the body’s ability to fight infections. It is recommended to postpone vaccination until the end of such treatment or disease. However, children with long standing problems with their immune system such as HIV infection (AIDS) may still be given Vaxelis but the protection may not be as good as in children with a healthy immune system.
- suffers from any undiagnosed illness of the brain or epilepsy which is not controlled. Your doctor or nurse will assess the potential benefit offered by vaccination, once the condition is stabilised.
- suffers from fits during a fever, or there is family history of fits occurring during a fever.
- has any problems with bleeding for a long time after minor cuts, or bruises easily. Your doctor will advise you whether your child should receive Vaxelis.
- was born very prematurely (at or before 28 weeks of gestation). In these infants, longer gaps than normal between breaths may occur for 2 to 3 days after vaccination.
Other medicines or vaccines and Vaxelis
Tell your doctor or nurse if your child is taking or has recently taken or might take any other medicines or vaccines.

Vaxelis can be given at the same time as other vaccines such as pneumococcal vaccines, measles-mumps-rubella-varicella (MMRV) vaccines, rotavirus vaccines, or meningococcal B or C vaccines.

Your doctor or nurse will give these injections at different sites and will use different syringes and needles for each injection.

Driving and using machines
It is expected that Vaxelis will have no or negligible influence on the ability to drive and use machines.

Vaxelis contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

3. How Vaxelis is given
Vaxelis will be given to your child by a doctor or nurse trained in the use of vaccines and who are equipped to deal with any uncommon severe allergic reaction to the injection (see section 4 Possible side effects).

Your doctor or nurse will inject Vaxelis into your child’s thigh (in infants from the age of 6 weeks) or arm (in children older than one year).

The recommended dose is as follows:

First course of vaccination (primary vaccination)
Your child will receive two or three injections given at least one month apart. Your doctor or nurse will tell you when your child should come back for their next injection as per the local vaccination program.

Additional injection (booster)
After the first course of injections, your child will receive a booster dose, in accordance with local recommendations, at least 6 months after the last dose of the first course. Your doctor will tell you when this dose should be given.

If your child misses a dose of Vaxelis
If your child misses a scheduled injection, it is important that you discuss with your doctor or nurse who will decide when to give the missed dose.

It is important to follow the instructions from the doctor or nurse so that your child completes the course of injections. If not, your child may not be fully protected against the diseases.

If you have any further questions on the use of this vaccine, ask your doctor, pharmacist or nurse.

4. Possible side effects
Like all medicines, this vaccine can cause side effects, although not everybody gets them.

Serious allergic reactions
If any of these symptoms occur after leaving the place where your child received his/her injection, you must consult a doctor IMMEDIATELY:
- difficulty in breathing
- blueness of the tongue or lips
- a rash
- swelling of the face or throat
- low blood pressure causing dizziness or collapse.

When these signs or symptoms occur they usually develop quickly after the injection is given and while the child is still in the clinic or doctor’s surgery.

Serious allergic reactions are very rare (may affect up to 1 in 10,000 people) and can occur after receiving any vaccine.

**Other side effects**

If your child experiences any of the following side effects, please tell your doctor, nurse or pharmacist.

- **Very common side effects (may affect more than 1 in 10 people) are:**
  - decreased appetite
  - irritability
  - crying
  - vomiting
  - sleepiness or drowsiness
  - fever (temperature 38°C or higher)
  - pain, redness, swelling at the injection site

- **Common side effects (may affect up to 1 in 10 people) are:**
  - diarrhoea
  - hard mass, lump (nodule) at the injection site
  - bruising at the injection site

- **Uncommon side effects (may affect up to 1 in 100 people) are:**
  - rash
  - warmth, rash at the injection site
  - increased appetite
  - stomach pain
  - excessive sweating
  - cough
  - nasal congestion and runny nose
  - paleness
  - sleep disorders including inability to get adequate sleep
  - restlessness
  - swollen glands in the neck, armpit or groin
  - feeling tired
  - floppiness

- **Rare side effects (may affect up to 1 in 1,000 people) are:**
  - allergic reaction, serious allergic reaction (anaphylactic reaction)
  - extensive swelling of the vaccinated limb

- **Side effects with frequency not known (frequency cannot be estimated from the available data) are:**
  - fits (convulsions) with or without fever
  - floppiness and unresponsive or unconscious and/or paleness or bluish skin

Other side effects not listed above have been reported with other diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B or Hib containing vaccines:
- episodes of shock-like state or paleness, floppy and unresponsive

**Reporting of side effects**

If your child gets any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting...
By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Vaxelis

Keep this vaccine out of the sight and reach of children.

Store in a refrigerator (2°C - 8°C). Do not freeze. Keep the vaccine in the outer carton in order to protect from light.

Do not use this vaccine after the expiry date which is stated on the carton and the label after EXP. The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. Contents of the pack and other information

What Vaxelis contains

The active substances per dose (0.5 mL):

- Diphtheria Toxoid
- Tetanus Toxoid
- Bordetella pertussis antigens
  - Pertussis Toxoid (PT)
  - Filamentous Haemagglutinin (FHA)
  - Pertactin (PRN)
  - Fimbriae Types 2 and 3 (FIM)
- Bordetella pertussis antigens
  - Pertussis Toxoid (PT)
  - Filamentous Haemagglutinin (FHA)
  - Pertactin (PRN)
  - Fimbriae Types 2 and 3 (FIM)
- Hepatitis B surface antigen
- Poliovirus (Inactivated)
  - Type 1 (Mahoney)
  - Type 2 (MEF-1)
  - Type 3 (Saukett)
- Haemophilus influenzae type b polysaccharide
  - (Polyribosylribitol Phosphate)
  - Conjugated to meningococcal protein

Aluminium phosphate and amorphous aluminium hydroxyphosphate sulphate are included in the vaccine as adjuvants. Adjuvants are included to improve the immune response of vaccines.

The other ingredients are:

- Sodium phosphate, water for injections

The vaccine may contain traces of glutaraldehyde, formaldehyde, neomycin, streptomycin, polymyxin B, and bovine serum albumin.

What Vaxelis looks like and contents of the pack

The normal appearance of the vaccine is a uniform, cloudy, white to off-white suspension, which may settle down during storage.
Vaxelis is provided as a suspension for injection in pre-filled syringe.

Pack size of 1 or 10 pre-filled syringes, without attached needle, with 1 separate needle or with 2 separate needles.
Multipack of 5 packs of 10 pre-filled syringes with no needle.

Not all pack sizes may be marketed.

**Marketing Authorisation Holder and Manufacturer**
MCM Vaccine B.V., Robert Boyleweg 4, 2333 CG Leiden, The Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**
MSD Belgium
Tél/Tel: +32(0)27766211
d poc_belux@msd.com

**Lietuva**
UAB Merck Sharp & Dohme
Tel. + 370 5 278 02 47
msd_lietuva@merck.com

**България**
Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3737
info-msdbg@merck.com

**Luxembourg/Luxemburg**
MSD Belgium
Tél/Tel: +32(0)27766211
d poc_belux@msd.com

**Česká republika**
Merck Sharp & Dohme s.r.o.
Tel: +420 233 010 111
d poc_czechslovak@merck.com

**Magyarország**
MSD Pharma Hungary Kft.
Tel.: +36 1 888 5300
hungary_msd@merck.com

**Danmark**
MSD Danmark ApS
Tlf.: +45 4482 4000
dkmail@merck.com

**Malta**
Merck Sharp & Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
malta_info@merck.com

**Deutschland**
MSD Sharp & Dohme GmbH
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)
e-mail@msd.de

**Nederland**
Merck Sharp & Dohme B.V.
Tel: 0800 9999000
(+31 23 5153153)
medicalinfo.nl@merck.com

**Eesti**
Merck Sharp & Dohme OÜ
Tel.: +372 6144 200
msdeesti@merck.com

**Norge**
MSD (Norge) AS
Tlf: +47 32 20 73 00
msdnorge@msd.no

**Ελλάδα**
MSD Α.Φ.Ε.Ε.
Τηλ: +30 210 98 97 300
d poc_greece@merck.com

**Österreich**
Merck Sharp & Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
d poc_austria@merck.com

**España**
Merck Sharp & Dohme de España, S.A.
Tel: +34 91 321 06 00
msd_info@merck.com

**Polska**
MSD Polska Sp. z o.o.
Tel: +48 22 549 51 00
msdpolska@merck.com
France
MSD France
Tél: + 33 (0) 1 80 46 40 40

Portugal
Merck Sharp & Dohme, Lda
Tel: +351 21 4465700
inform_pt@merck.com

Hrvatska
Merck Sharp & Dohme d.o.o.
Tel: + 385 1 6611 333
croatia_info@merck.com

România
Merck Sharp & Dohme Romania S.R.L.
Tel: +40 21 529 29 00
msdromania@merck.com

Ireland
Merck Sharp & Dohme Ireland (Human Health) Limited
Tel: +353 (0)1 2998700
medinfo_ireland@msd.com

Slovenija
Merck Sharp & Dohme, inovativna zdravila d.o.o.
Tel: +386 1 5204 201
msd.slovenia@merck.com

Ísland
Vistor hf.
Simi: + 354 535 7000

Slovenská republika
Merck Sharp & Dohme, s. r. o.
Tel: +421 2 58282010
dpoc_czechslovak@merck.com

Italia
MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
medicalinformation.it@msd.com

Suomi/Finland
MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
info@msd.fi

Kύπρος
Merck Sharp & Dohme Cyprus Limited
Tηλ.: 800 00 673 (+357 22866700)
cyprus_info@merck.com

Sverige
Merck Sharp & Dohme (Sweden) AB
Tel: +46 77 5700488
medicinsinfo@merck.com

Latvija
SIA Merck Sharp & Dohme Latvija
Tel: + 371 67364224
msd_lv@merck.com

United Kingdom (Northern Ireland)
Sanofi
Tel: +44 845 372 7101

This leaflet was last revised in {month YYYY}.

Detailed information on this medicine is available on the European Medicines Agency web site:

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.

The following information is intended for healthcare professionals only:

The pre-filled syringe should be shaken gently in order to obtain a homogeneous, whitish, cloudy suspension.

The suspension should be visually inspected, prior to administration, for foreign particulate matter and/or variation of physical appearance. If either is observed, discard the pre-filled syringe.

The needle must be fitted firmly on to the pre-filled syringe, rotating it by a one-quarter turn.

Vaxelis is for intramuscular injection only.
The recommended injection sites are the anterolateral aspect of the thigh or the deltoid region of the upper arm if there is adequate muscle mass. The anterolateral aspect of the thigh is the preferred site for infants under one year of age.